Home » Testosterone Clinical Trials

Testosterone Clinical Trials

Bookmarkx

Testosterone Benefits

Testosterone Replacement Therapy has enormous benefits for men experiencing symptoms due to Andropause (Male Menopause) Learn about Testosterone Replacement Therapy, (TRT), Testosterone Injections and Creams, Male Hormone Therapy and Male Hormone Health at the Anti-Aging Medical Group.


To learn more about testosterone, low t symptoms, low testosterone treatment and bio-identical testosterone therapy to increase testosterone levels with hormone replacement injections, visit Testosterone Therapy & Testosterone Injection Treatments


Testosterone Clinical Trials

1. Newly Approved Drug Therapies (23): Androderm (Testosterone

Listing for Androderm (Testosterone Transdermal System) in FDA Approved Drug
Therapies Archives from CenterWatch Clinical Trials Listing Service.

Testosterone transdermal patches are used to treat the symptoms of low testosterone in men whose bodies do not produce enough natural testosterone. Testosterone, a hormone that is usually produced by the body, contributes to the growth, development, and functioning of the male sexual organs and typical male characteristics. Symptoms of low testosterone include decreased sexual desire and ability, extreme tiredness, low energy, depression, and loss of certain male characteristics such as muscular build and deep voice. Testosterone patches work by providing a steady supply of testosterone through the skin to the body.

Learn more about Testosterone Therapy at The Anti-Aging Group Male Hormone Therapy center – Testosterone Therapy

2. Newly Approved Drug Therapies (611): AndroGel Testosterone Gel

Listing for AndroGel Testosterone Gel in FDA Approved Drug Therapies Archives from CenterWatch Clinical Trials Listing Service. 

Learn more about Testosterone Treatment for Low Testosterone at The Anti-Aging Group Male Hormone Therapy Center – Testosterone Treatment

3. Disease Category Listing (646): Low Testosterone Clinical Trials:

CenterWatch Listing of Clinical Research Trials for Low Testosterone.

Learn more about Testosterone Treatment for Low Testosterone at The Anti-Aging Group Male Hormone Therapy Center – Low Testosterone Treatment

4. Study Posting – Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement

CenterWatch Clinical Research Trial Posting for Men. Have you been told you have Low Testosterone?

Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement

Dutasteride in Men Receiving Testosterone Therapy: Impact on Serum PSA, Testosterone, DHT Levels and Prostate Volume: “Implications for Prostate Safety”

This is a study using two FDA approved medications: Testosterone and the study medication, Dutasteride (Avodart 0.5mg/day). Half of the subjects will receive dutasteride and half will receive a placebo. The study medication will be taken for 12 months.

5. Study Posting (North Jersey) — Trial #54769, Low Testosterone

CenterWatch Clinical Research Trial Posting for Men age 18 to 75 in North Jersey:
Men age 18 to 75 in North Jersey: Have you been told you have Low Testosterone? If a blood test was done and you have been told you have low testosterone you may qualify for a clinical research study…

6. Study Posting (Viagra) — Viagra Trial, Low Testosterone

Viagra Clinical Study. CenterWatch Clinical Research Trial Posting for To the Viagra user: Do you have
these problems? Lack of energy, Low sex drive, Falling asleep after dinner.

7. Newly Approved Drug Therapies (810): Testim, Auxilium Pharmaceuticals

Testim is an externally administered Testosterone supplement, Testosterone is
responsible for normal growth and development of the male sex organs

Learn more about Testosterone Hormone Replacement for Low Testosterone at The Anti-Aging Group Male Hormone Therapy Center – Testosterone Replacement

8. Wondering if your Testosterone is Low (Covance Clinical Trial):

Wondering if your testosterone is low?

Covance is looking for overweight men at 55+ with low testosterone to participate in a clinical research study involving an investigational testosterone medication.

9. The Testosterone Trial (The T Trial):

The Testosterone Trial – Can testosterone treatment improve unwanted effects of aging in older men?

The Testosterone Trial (“The T Trial for short”) is a national study in older men who have low blood levels of testosterone. The main goal of The T Trial is to learn if using testosterone for one year will improve walking, sexual function, energy and memory. About 800 men, age 65 or older, in twelve regions across the United States will participate in The T Trial. Testosterone is the major male hormone. It plays an important role in muscle and bone strength, sex drive, energy level and memory. In many men, the amount of testosterone in the blood gradually decreases with age.

Research suggests that having low testosterone levels may cause some of the unwanted effects of aging. A blood test is the only way to learn what your testosterone level is.

10. Normalization of Morning Testosterone Levels in Men:

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism (Low Testosterone), That Wish to Maintain Their Reproductive Status

A Randomized, Double Blind, Placebo and Active Controlled, Parallel, Multi-Center Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism With Confirmed Morning Testosterone Levels <250 ng/dL That Wish to Preserve Their Reproductive Status and Are Not Currently Being Treated With Topical Testosterone

The Purpose of the study is to determine the effects of Androxal on morning testosterone and reproductive status in men with secondary hypogonadism(confirmed morning Testosterone less than 250 ng/dL), compared to changes with placebo, or Testim (topical testosterone). The effects of Testim versus placebo on reproductive status will also be examined. Study subjects must not be currently using a topical testosterone.

11.
Newly Approved Drug Therapies (609): Viadur (leuprolide acetate
Viadur is a testosterone suppression therapy for the palliative treatment
12 months of testosterone suppression therapy in a single administration.
12.
Study Posting Men’s Health (Clinical Trials)

Men’s Health CenterWatch Clinical Research Trial Posting for Low Testosterone / Hypogonadism Research Study.
men who have been diagnosed with low testosterone to participate in a

13.
Study Posting (Clinical Trial Results) — Hypogonadism

CenterWatch Clinical Research Trial Posting for Low Testosterone Medications Clinical Trial results for men who have been diagnosed with hypogonadism

 

14.
Study Posting (Clinical Trials) — Listing for Hypogonadism, Pituitary Disorders

CenterWatch Clinical Research Trial Posting for Clinical Trials recruiting men with hypogonadism pituitary
disease experiencing testosterone and growth hormone deficiencies…

15.
Clinical Trials Research Study (Androgen Deficiency & Osteoporosis)

Clinical Trials: Osteoporosis. Androgen deficiency (low testosterone) and osteoporosis listing of clinical trials currently looking for volunteers to enroll in Osteoporosis studies…

 

16.
Male Hormone Deficiencies (Testim Clinical Trial Results):

Testim is an externally administered testosterone supplement, Testosterone is
responsible for normal growth and development of the male sex organs…

Auxilium Pharmaceuticals has reported the results of a phase IV study of their topical testosterone therapy Testim, for the treatment of hypogonadism in men unable to achieve symptom amelioration with AndroGel, another topical testosterone therapeutic. The study found that Testim therapy was effective in treating symptoms of hypogonadism, significantly improving sexual function and satisfaction, compared with men remaining on a comparable dose of AndroGel…

17.
Clinical Study The Cardiac Benefit of Testosterone Replacement in Men:

The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart ArteryThe Cardiac Benefit of Androgen Replacement in Hypogonadal Males With Coronary Artery Disease Following Successful Percutaneous Coronary Intervention (PCI)… The purpose of the study is to find out if giving the study drug, Androgel (testosterone) as a testosterone replacement help bring the testosterone to an acceptable level and to find out if it will help improve heart condition in males with coronary artery disease (CAD) following successful percutaneous coronary intervention…

 

18.
Clinical Trial Testosterone: (Erectile Dysfunction / Premature Ejaculation)

Testosterone can be injected or  placed on different parts of the body, boosts testosterone levels.
andropause or hypogonadism is a condition in which the body produces inadequate levels of testosterone.

Premature Ejaculation and Erectile Dysfunction Clinical Research Study. Are you being treated for Erectile Dysfunction (ED) and also experiencing the condition of Premature Ejaculation (PE)?  Erectile dysfunction (ED) is a condition in which the penis does not become hard or expand when a man is sexually aroused, or when this change cannot be maintained to permit sexual intercourse… Premature Ejaculation (PE) is a sexual dysfunction in men characterized by ejaculation which always or nearly always occurs before or within one minute of vaginal penetration and the inability to delay ejaculation on all or nearly all vaginal penetrations. PE is often associated with negative personal consequences, such as distress, bother, frustration, and/or the avoidance of sexual intimacy.

Learn more about Testosterone Therapy, Testosterone Injections Testosterone Cream and Gel at The Anti-Aging Group Male Hormone Therapy Clinic – Testosterone Replacement Therapy

19.
Study Posting (2946) — Trial #54813, HIV, Los Angeles, CA
CenterWatch Clinical Research Trial Posting for Testosterone Replacement and
Physical Function in HIV-Associated Weight Loss.
20.
Male Research Study (Low Testosterone & Type 2 Diabetes):

Low testosterone conditions associated with a deficiency or absence of endogenous testosterone
treated with mediciations that delivers testosterone and lowers blood sugar

Research Study for Men with Type 2 Diabetes and Low Testosterone

Seeking males, ages 20 to 80 years, taking oral medication for type 2 diabetes, but blood sugar remains high, and having low testosterone, or symptoms of low testosterone (fatigue, erectile dysfunction, decreased sexual desire, mood disturbance, and loss of energy) …

Previous work has shown that the experimental treatment has led to increases of testosterone to a normal range. The purpose of this study is to determine if this medication can also decrease blood sugar levels in men who are type 2 diabetics..

21.
AAFA Home Page
Somavert (pegvisomant), an analog of human growth hormone, is an injectable medication
that has been structurally altered to act as a growth hormone (GH
22.
Publications | Black AIDS Institute: …
Summary: Testosterone Replacement and Physical Function in HIV-Associated Weight
Loss. Many men with HIV have low levels of testosterone in their blood.

23.
Publications | Black AIDS Institute: …
Summary: Testosterone Replacement and Physical Function in HIV-Associated Weight
Loss. Many men with HIV have low levels of testosterone in their blood.
24.
Newly Approved Drug Therapies (609): Viadur (leuprolide acetate …: …
Viadur is a testosterone suppression therapy for the palliative treatment
12 months of testosterone suppression therapy in a single administration.

25.
Publications | Black AIDS Institute
Drug Name: Androderm (Testosterone Transdermal System) a skin patch that
can be placed on different parts of the body, boosts testosterone levels.
26.
Drugs Approved by the FDA: …
In clinical trials, Androderm restored normal testosterone levels in 86 of 94
Transdermal patches offer alternatives to testosterone injections,
27.
Publications | Black AIDS Institute:
of HIV-infection with low to low-normal testosterone levels (< 400 ng/dL).
of age-related changes in testosterone levels and body composition,
28.
RESOLVE: The National Infertility Association:
Men Age 18 to 75 in New Jersey: Have you been told you have Low Testosterone?
Lawrenceville; LU Clinical Research To the Viagra user: Do you have these

29.
Drugs Approved by the FDA:
The gel is absorbed through the skin and delivers testosterone to the patient
In addition to supplying sufficient amounts of testosterone, AndroGel,
30.
MPIP – Clinical Trials Resource Center:
Viadur is a testosterone suppression therapy for the palliative treatment
12 months of testosterone suppression therapy in a single administration.
31.
Study Posting (1521) — Trial #69163, *Healthy Patient Studies …:
CenterWatch Clinical Research Trial Posting for Low Testosterone Research Study.
who have been diagnosed with low testosterone to participate in a
32.
Study Posting (2946) — Trial #54813, HIV, Los Angeles, CA:
CenterWatch Clinical Research Trial Posting for Testosterone Replacement and
Physical Function in HIV-Associated Weight Loss.

33.
Study Posting (488) — Trial #59855, Pituitary Disorders …:
CenterWatch Clinical Research Trial Posting for Recruiting men with pituitary
disease who have testosterone and growth hormone deficiencies.

34.
Sexual Dysfunction:
Testosterone and other hormone injections low testosterone levels, and
are generally ineffec- gen and testosterone affected by age, surgery or
35.
AAFA Home Page:
serum testosterone levels first increased, peaking on day 4, Similar
testosterone profiles were observed in patients with advanced prostate cancer,
36.
Newly Approved Drug Therapies (375): Testoderm TTS CIII, Alza:
Testoderm TTS CIII has been approved for men with testosterone deficiency.
It is a transdermal patch that delivers a 5-mg dose of testosterone during a

37.
Newly Approved Drug Therapies (736): Eligard (leuprolide acetate …:
decrease testosterone to suppress tumor growth in patients with in levels
of the gonadal steroids (testosterone and dihydrotestosterone in males,
38.
Drugs Approved by the FDA:
Viadur is a testosterone suppression therapy for the palliative treatment
12 months of testosterone suppression therapy in a single administration.

39.
UrologyHealth.org – Clinical Trials Resource Center:
Viadur is a testosterone suppression therapy for the palliative treatment
12 months of testosterone suppression therapy in a single administration.
40.
BioWorld | Clinical Trials Resource Center:
Viadur is a testosterone suppression therapy for the palliative treatment
12 months of testosterone suppression therapy in a single administration.
41.
UrologyHealth.org – Clinical Trials Resource Center:
The growth of prostate cancer can be stimulated by the male hormone testosterone.
as a subcutaneous injection results in a decline in testosterone,
42.
BioWorld | Clinical Trials Resource Center:
Testim is an externally administered testosterone supplement, Testosterone is
responsible for normal growth and development of the male sex organs
43.
Newly Approved Drug Therapies (846): Plenaxis (abarelix for …:
hormone (GnRH) antagonist, lowers the male hormone testosterone in the blood
stream. Testosterone makes some prostate cancers grow.

44.
Drugs Approved by the FDA:
Drug Name: Androderm (Testosterone Transdermal System). Androderm, a skin patch that
can be placed on different parts of the body, boosts testosterone levels.
45.
UrologyHealth.org – Clinical Trials Resource Center:
cancer. General Information. Viadur is a testosterone suppression therapy
for the palliative treatment of advanced prostate cancer.
46.
Publications | Black AIDS Institute:
Drug Name: Androderm (Testosterone Transdermal System). Androderm, a skin patch that
can be placed on different parts of the body, boosts testosterone levels.
47.
MPIP – Clinical Trials Resource Center:
Sustained levels of leuprolide, a luteinizing hormone-releasing hormone (LHRH) agonist,
decrease testosterone to suppress tumor growth in patients with hormone
48.
MPIP – Clinical Trials Resource Center:
  Sustained levels of leuprolide, a luteinizing hormone-releasing hormone (LHRH) agonist,
decrease testosterone to suppress tumor growth in patients with hormone
49.
Publications | Black AIDS Institute:
cancer. General Information. Viadur is a testosterone suppression therapy
for the palliative treatment of advanced prostate cancer.

50.
MPIP – Clinical Trials Resource Center:

Company: Alza Approval Status: Approved December 1997 Treatment for: testosterone
deficiency. General Information. Testoderm TTS CIII

51.
BioWorld | Clinical Trials Resource Center:
Company: Auxilium Pharmaceuticals Approval Status: Approved October 2002
Treatment for: Low Testosterone. General Information. Testim
52.
Listing of Newly Approved Drug Therapies (2000):
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000.
53.
MPIP – Clinical Trials Resource Center:
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000.
54.
Newly Approved Drug Therapies (38): Zoladex (10.8 mg goserelin …:
The growth of prostate cancer can be stimulated by the male hormone testosterone.
Treatment with Zoladex as a subcutaneous injection

55.
Centerwatch:
Viadur is a testosterone suppression therapy for the palliative treatment
12 months of testosterone suppression therapy in a single administration.
56.
Drugs Approved by the FDA:
The growth of prostate cancer can be stimulated by the male hormone testosterone.
as a subcutaneous injection results in a decline in testosterone,
57.
Study Posting (16) — Trial #43225, Prostate Cancer, Jackson, MS:
dose of FE200486 for reducing testosterone levels in men with prostate cancer,
the growth of cancer cells is stimulated by the hormone testosterone,
58.
AAFA Home Page:
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000
59.
BioWorld | Clinical Trials Resource Center:
serum testosterone levels first increased, peaking on day 4, Similar
testosterone profiles were observed in patients with advanced prostate cancer,
60.
RESOLVE: The National Infertility Association:
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000
61.
Drugs Approved by the FDA:
hormone (GnRH) antagonist, lowers the male hormone testosterone in the blood
stream. Testosterone makes some prostate cancers grow.
62.
Drugs Approved by the FDA (2000):
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000
63.
Centerwatch:
Summary: Recruiting men with pituitary disease who have testosterone and
Both testosterone and growth hormone individually improve bone density in

64.
Centerwatch:
Age 18 to 75 in New Jersey: Have you been told you have Low Testosterone?
you have low testosterone, you may qualify for a clinical research study.
65.
BioWorld | Clinical Trials Resource Center:
decrease testosterone to suppress tumor growth in patients with in levels
of the gonadal steroids (testosterone and dihydrotestosterone in males,
66.
Centerwatch:
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000
67.
Publications | Black AIDS Institute:
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000

68.
Centerwatch:
also have the problems listed above, you may have a testosterone level that
is below normal. Some Viagra users have a low blood level of testosterone.
69.
Resources – The Breast Cancer Fund:
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000
70.
Centerwatch:
told you have low testosterone you may qualify for a clinical research study.
With low testosterone you will frequently also have lack of energy and low

71.
BioWorld | Clinical Trials Resource Center:
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000
72.
Approved Drugs for Endocrinology:
AndroGel testosterone gel; For testosterone replacement therapy in males with
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza;

73.
AAFA Home Page:
AndroGel testosterone gel; For testosterone replacement therapy in males with
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza;
74.
Drugs Approved by the FDA:
Testoderm TTS CIII has been approved for men with testosterone deficiency.
It is a transdermal patch that delivers a 5-mg dose of testosterone during a

75.
Newly Approved Drug Therapies (719): Trelstar LA, Debiopharm:
in the Quality of Life scale during treatment, and testosterone pharmacodynamics.
In men, a reduction in serum testosterone concentration to a level
76.
Drugs Approved by the FDA:
in the Quality of Life scale during treatment, and testosterone pharmacodynamics.
In men, a reduction in serum testosterone concentration to a level
77.
Clinical Trials Resource Center – Hepatitis Foundation International:
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000

78.
BioWorld | Clinical Trials Resource Center:
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza;
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
79.
Centerwatch:
in the Quality of Life scale during treatment, and testosterone pharmacodynamics.
In men, a reduction in serum testosterone concentration to a level
80.
RESOLVE: The National Infertility Association:
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000
81.
The SHADE Foundation – The Curt and Shonda Schilling Melanoma …:
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000

82.
Publications | Black AIDS Institute:
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza;
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
83.
UrologyHealth.org – Clinical Trials Resource Center:
Age 18 to 75 in New Jersey: Have you been told you have Low Testosterone?
you have low testosterone, you may qualify for a clinical research study.
84.
Centerwatch:
Radiant Research is seeking men 18-65 years old, who have been diagnosed with
low testosterone to participate in a clinical research study for an

85.
UrologyHealth.org – Clinical Trials Resource Center:
also have the problems listed above, you may have a testosterone level that
is below normal. Some Viagra users have a low blood level of testosterone.

86.
UrologyHealth.org – Clinical Trials Resource Center:
age 18 to 75 in North Jersey: Have you been told you have Low Testosterone?
you have low testosterone you may qualify for a clinical research study.
87.
Centerwatch:
Summary: Recruiting men with pituitary disease who have testosterone and
Both testosterone and growth hormone individually improve bone density in
88.
AADE | Clinical Trials Resource Center:
Summary: Recruiting men with pituitary disease who have testosterone and
Both testosterone and growth hormone individually improve bone density in

89.
Newly Approved Drug Therapies (40): Lupron Depot (leuprolide …:
22.5 mg) works by shutting down the production of the hormone testosterone,
Decreasing the levels of testosterone in the body also alleviates the

90.
RESOLVE: The National Infertility Association:
AndroGel testosterone gel; For testosterone replacement therapy in males with
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza;

91.
AADE | Clinical Trials Resource Center:
decrease testosterone to suppress tumor growth in patients with in levels
of the gonadal steroids (testosterone and dihydrotestosterone in males,
92.
BioWorld | Clinical Trials Resource Center:
hormone (GnRH) antagonist, lowers the male hormone testosterone in the blood
stream. Testosterone makes some prostate cancers grow.
93.
Centerwatch:
The growth of prostate cancer can be stimulated by the male hormone testosterone.
as a subcutaneous injection results in a decline in testosterone,
94.
Clinical Trials Resource Center:
Viadur is a testosterone suppression therapy for the palliative treatment
12 months of testosterone suppression therapy in a single administration.

95.
DEPARTMENT OF HEALTH & HUMAN SERVICES q34@q Via FEDEX WARNING …:
96.
AADE | Clinical Trials Resource Center:
decrease testosterone to suppress tumor growth in patients with in levels
of the gonadal steroids (testosterone and dihydrotestosterone in males,
97.
BioWorld | Clinical Trials Resource Center:
hormone (GnRH) antagonist, lowers the male hormone testosterone in the blood
stream. Testosterone makes some prostate cancers grow.
98.
Clinical Trials Resource Center:
Viadur is a testosterone suppression therapy for the palliative treatment
12 months of testosterone suppression therapy in a single administration.
99.
Clinical Trials Resource Center:
Viadur is a testosterone suppression therapy for the palliative treatment
12 months of testosterone suppression therapy in a single administration.
100.
Centerwatch:
decrease testosterone to suppress tumor growth in patients with in levels
of the gonadal steroids (testosterone and dihydrotestosterone in males,

101.
BioWorld | Clinical Trials Resource Center:
in the Quality of Life scale during treatment, and testosterone pharmacodynamics.
In men, a reduction in serum testosterone concentration to a level
102.
Epilepsy Fdn.-Research Home Page:
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000
103.
Centerwatch:
Testoderm TTS CIII has been approved for men with testosterone deficiency.
It is a transdermal patch that delivers a 5-mg dose of testosterone during a
104.
Drugs Approved by the FDA:
Serum testosterone levels may increase approximately 50 percent above baseline
It works by inhibiting the production of the hormone testosterone,
105.
AADE | Clinical Trials Resource Center:
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000
106.
Newly Approved Drug Therapies (371): Propecia, Merck:
which is responsible for the formation of dihydro-testosterone in a man’s body.
The enzyme converts testosterone to DHT, and it is believed that DHT is
107.
Epilepsy Fdn.-Research Home Page:
AndroGel testosterone gel; For testosterone replacement therapy in males with
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza;
108.
BioWorld | Clinical Trials Resource Center:
Serum testosterone levels may increase approximately 50 percent above baseline
It works by inhibiting the production of the hormone testosterone,
109.
AADE | Clinical Trials Resource Center:
AndroGel testosterone gel; For testosterone replacement therapy in males with
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza;
110.
Clinical Trials Resource Center:
The growth of prostate cancer can be stimulated by the male hormone testosterone.
as a subcutaneous injection results in a decline in testosterone,

111.
Clinical Trials Resource Center:
hormone (GnRH) antagonist, lowers the male hormone testosterone in the blood
stream. Testosterone makes some prostate cancers grow.
112.
AADE | Clinical Trials Resource Center:
hormone (GnRH) antagonist, lowers the male hormone testosterone in the blood
stream. Testosterone makes some prostate cancers grow.

113.
Centerwatch:
AndroGel testosterone gel; For testosterone replacement therapy in males with
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza;
114.
Clinical Trials Resource Center:
AndroGel testosterone gel; For testosterone replacement therapy in males with
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza;
115.
Clinical Trials Resource Center:
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000

116.
Clinical Trials Resource Center:
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000
117.
Study Posting (3115) — Trial #65468, Erectile Dysfunction, New …
CenterWatch Clinical Research Trial Posting for Testim – A research study for
men with low testosterone.
118.
Clinical Trials Resource Center:
in the Quality of Life scale during treatment, and testosterone pharmacodynamics.
In men, a reduction in serum testosterone concentration to a level
119.
Study Posting (2946) — Trial #50488, Pituitary Disorders, Los …:
To Undergo Baseline Studies to Evaluate Consequences of Low Testosterone and
To Receive Testosterone Replacement for 2 Months.
120.
Study Posting (799) — Trial #61183, HIV, Boston, MA:
a research drug to treat low level testosterone levels (androgen deficiency).
A. HIV-positive women (age 18-45) with low blood testosterone levels
121.
Study Posting (2676) — Trial #69515, Prostate Cancer, Houston, TX:
medication to see if it helps reduce bone loss and fractures in men with
prostate cancer who are being treated with testosterone reduction therapy.
122.
Study Posting (2676) — Trial #69516, Osteoporosis, Houston, TX:
medication to see if it helps reduce bone loss and fractures in men with
prostate cancer who are being treated with testosterone reduction therapy.
123.
Clinical Trials Resource Center:
AndroGel testosterone gel; For testosterone replacement therapy in males with
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza;

124.
Drugs Approved by the FDA:
which is responsible for the formation of dihydro-testosterone in a man’s body.
The enzyme converts testosterone to DHT, and it is believed that DHT is

125.
Drugs Approved by the FDA:
22.5 mg) works by shutting down the production of the hormone testosterone,
Decreasing the levels of testosterone in the body also alleviates the
126.
Clinical Trials Resource Center:
AndroGel testosterone gel; For testosterone replacement therapy in males with
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza;
127.
UrologyHealth.org – Clinical Trials Resource Center:
Summary: Testim – A research study for men with low testosterone.
Documented low testosterone. Current treatment of Cialis, Levitra,
128.
BioWorld | Clinical Trials Resource Center:
22.5 mg) works by shutting down the production of the hormone testosterone,
Decreasing the levels of testosterone in the body also alleviates the
129.
BioWorld | Clinical Trials Resource Center:
which is responsible for the formation of dihydro-testosterone in a man’s body.
The enzyme converts testosterone to DHT, and it is believed that DHT is

130.
UrologyHealth.org – Clinical Trials Resource Center:
22.5 mg) works by shutting down the production of the hormone testosterone,
Decreasing the levels of testosterone in the body also alleviates the

131.
Centerwatch:
which is responsible for the formation of dihydro-testosterone in a man’s body.
The enzyme converts testosterone to DHT, and it is believed that DHT is
132.
Centerwatch:
To Undergo Baseline Studies to Evaluate Consequences of Low Testosterone and
To Receive Testosterone Replacement for 2 Months.
133.
Centerwatch:
22.5 mg) works by shutting down the production of the hormone testosterone,
Decreasing the levels of testosterone in the body also alleviates the
134.
AADE | Clinical Trials Resource Center:
22.5 mg) works by shutting down the production of the hormone testosterone,
Decreasing the levels of testosterone in the body also alleviates the
135.
Osteoporosis:
low testosterone levels in men. Chronically low. dietary calcium intake, use
of corticosteroids or. anticonvulsants, smoking, sedentary lifestyle

136.
Centerwatch:
To Undergo Baseline Studies to Evaluate Consequences of Low Testosterone and
To Receive Testosterone Replacement for 2 Months.
137.
Centerwatch:
22.5 mg) works by shutting down the production of the hormone testosterone,
Decreasing the levels of testosterone in the body also alleviates the
138.
AADE | Clinical Trials Resource Center:
22.5 mg) works by shutting down the production of the hormone testosterone,
Decreasing the levels of testosterone in the body also alleviates the
139.
Clinical Trials Resource Center:
22.5 mg) works by shutting down the production of the hormone testosterone,
Decreasing the levels of testosterone in the body also alleviates the

140.
Osteoporosis:
low testosterone levels in men. Chronically low. dietary calcium intake, use
of corticosteroids or. anticonvulsants, smoking, sedentary lifestyle
141.
Study Posting (2246) — Trial #50408, Breast Cancer, Duarte, CA:
investigational drug deslorelin, plus partial replacement of estrogen and
testosterone with a second nasal spray and of progesterone given as a pill.
142.
Study Posting (799) — Trial #49704, *Healthy Patient Studies …:
A six-week research study on the effects of testosterone and estrogen on bone
metabolism. The study involves two inpatient visits, one outpatient visit,

143.
Disease Category Listing (371): Erectile Dysfunction:
Testim – A research study for men with low testosterone. New York; University
Urology Associates A research study for men with erectile dysfunction
144.
Study Posting (799) — Trial #66689, *Healthy Patient Studies …:
the ages of 20-50 for a 16 week research study of the effects of testosterone
and estrogen on bone metabolism, body composition, strength, and symptoms.
145.
Newly Approved Drug Therapies (136): Eulexin (flutamide), Schering …:
which act by directly blocking the cancer-promoting activities of androgens,
or male sex hormones, of which the principal one is testosterone.

146.
CenterWatch Clinical Trials Listing in Nephrology/Urology:
Liver Cancer (6); Liver Disease (6); Liver Disorders (6); Low Blood
Sodium (Hyponatremia); Low Testosterone (3); Mastectomy; Medical Prosthetics
147.
Study Posting (713) — Trial #69076, Healthy Women Studies …:
should have a history of less than 6 menstrual cycles per year, as well as
elevated testosterone levels and/or problems with increased hair growth.
148.
Disease Category Listing (417): HIV:
Testosterone Replacement and Physical Function in HIV-Associated Weight Loss.
Los Angeles; UCLA Medical Center Phase II, double blind,
149.
Disease Category Listing: Healthy Patient Studies:
Low Testosterone Research Study. Various Cities; Research Site Rosuvastatin
in the primary prevention of cardiovascular disease among patients with Low

150.
The American Pain Foundation: …
selective androgen receptor modulator ostarine, for the treatment of andropause,
sarcopenia, and other symptoms of testosterone deficiency.
151.
Disease Category Listing: Healthy Patient Studies:
Low Testosterone Research Study. Various Cities; Research Site Rosuvastatin
in the primary prevention of cardiovascular disease among patients with Low

152.
Study Posting (1420) — Trial #49034, HIV, Los Angeles, CA:

The use of any steroids other than testosterone replacement therapy.
Participants with significant cardiac disease. Use of appetite stimulants within 6

153.
Newly Approved Drug Therapies (733): dutasteride, GlaxoSmithKline:
These enzymes are responsible for converting testosterone into
dihydrotestosterone (DHT) in the prostate. In turn, high levels of DTH may
accumulate and
154.
Study Posting (2623) — Trial #69732, Post Menopause, Aventura, FL:
The study will evaluate a combination medication of estrogen and testosterone
to alleviate these symptoms. To qualify:. Women 30 to 65 years old.
155.
Newly Approved Drug Therapies (707): Estrostep (ethinyl estradiol …:
The combination of norethindrone acetate and ethinyl estradiol increases sex
hormone binding globulin (SHBG) and decreases free testosterone; however,
156.
CenterWatch Clinical Research Center Profile (2380): LU Clinical …:
Males with BPH (Enlarged Prostate); Men Age 18 to 75 in New Jersey: Have you
been told you have Low Testosterone? Men age 18 to 75 in North Jersey: Have

157.
Welcome to the CenterWatch Research Headlines.:
selective androgen receptor modulator ostarine, for the treatment of andropause,
sarcopenia, and other symptoms of testosterone deficiency.

158.
Study Posting (799) — Trial #66690, Erectile Dysfunction, Boston, MA:

A research study of an investigational drug that increases testosterone levels
in men. Study duration is 12 months and involves 4 outpatient vists with

159.
Study Posting (3039) — Trial #55355, Prostate Cancer, Urbana, IL:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
160.
Study Posting (3039) — Trial #61874, Prostate Cancer, Baltimore, MD:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
161.
Study Posting (3039) — Trial #56704, Prostate Cancer, Davenport, IA:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
162.
Study Posting (3039) — Trial #53027, Prostate Cancer, Galesburg, IL:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
163.
Study Posting (3039) — Trial #53029, Prostate Cancer, Greensboro, NC:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
164.
Study Posting (3039) — Trial #61871, Prostate Cancer, Pittsburgh, PA:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
165.
Study Posting (3039) — Trial #64254, Prostate Cancer, Charleston, SC:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
166.
Study Posting (3039) — Trial #58282, Prostate Cancer, Milwaukee, WI:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
167.
Study Posting (3039) — Trial #53027, Prostate Cancer, Galesburg, IL:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
168.
Study Posting (3039) — Trial #53029, Prostate Cancer, Greensboro, NC:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron

169.
Study Posting (3039) — Trial #61871, Prostate Cancer, Pittsburgh, PA:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
170.
Study Posting (3039) — Trial #64254, Prostate Cancer, Charleston, SC:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron

171.
Study Posting (3039) — Trial #58282, Prostate Cancer, Milwaukee, WI:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
172.
Study Posting (3039) — Trial #53020, Prostate Cancer, Salt Lake …:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
173.
Study Posting (2439) — Trial #55225, Cancer Prevention, Voorhees, NJ:
.. the past 12 months of finasteride (Proscar or Propecia), dutasteride (Avodart),
testosterone, or drugs that can block the action of male hormones.

174.
AAFA Home Page:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
175.
Study Posting (3039) — Trial #54553, Prostate Cancer …:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
176.
Study Posting (3039) — Trial #56702, Prostate Cancer, Nyack, NY:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron

177.
CenterWatch Clinical Research Center Profile (2069 …:
Ocular Steroid; Pediculocide; Quinolone Antibiotic; Red Blood Cell Production
Stimulant; Testosterone Gel; Topical Antibiotic; Topical Hormone Gel
178.
Study Posting (3039) — Trial #64253, Prostate Cancer, Arlington, TX:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
179.
RESOLVE: The National Infertility Association:

selective androgen receptor modulator ostarine, for the treatment of andropause,
sarcopenia, and other symptoms of testosterone deficiency.

180.
Study Posting (2946) — Trial #50532, Kidney Failure, Los Angeles, CA:
18 years and older are invited to participate in a research study on testosterone
and its effects on muscle strength and physical function.
181.
Study Posting (558) — Trial #53556, Cancer Prevention, Billings, MT:
within the past 12 months of finasteride (Proscar or Propecia),
dutasteride (Avodart), testosterone, or drugs that can block the action of male
hormones
182.
Study Posting (3039) — Trial #58283, Prostate Cancer, New Port …:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
183.
Study Posting (3039) — Trial #54552, Prostate Cancer, Boston, MA:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
184.
Drugs Approved by the FDA (1995):
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
185.
Study Posting (3039) — Trial #54554, Prostate Cancer, Loma Linda, CA:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron

186.
CenterWatch Clinical Research Center Profile (16): Hudson Valley …:
ED; prostate cancer; UTI; testosterone replacement; TUMT/urinary retention;
overactive bladder; high grade PIN; complex PSA; outpatient surgical pain

187.
Study Posting (3039) — Trial #53024, Prostate Cancer, Fresno, CA:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
188.
Study Posting (3039) — Trial #56699, Prostate Cancer, La Mesa, CA:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
189.
CenterWatch Clinical Research Center Profile (2022): Urology Group …:
Group of New Mexico has performed clinical studies on prostate and bladder
cancer, BPH, female incontinence, prostatitis and testosterone studies.
190.
Study Posting (3039) — Trial #59282, Prostate Cancer, Albany, NY:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
191.
Study Posting (3039) — Trial #53019, Prostate Cancer, Dallas, TX:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron

192.
Study Posting (3039) — Trial #66845, Prostate Cancer, Atlanta, GA:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron

193.
Study Posting (3039) — Trial #59280, Prostate Cancer …:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron

194.
Study Posting (3039) — Trial #56701, Prostate Cancer, Richmond, VA:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
195.
Study Posting (3039) — Trial #53023, Prostate Cancer, Coeur D …:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron

196.
Disease Category Listing: Healthy Patient Studies:
Low Testosterone Research Study. Various Cities; Research Site Rosuvastatin
in the primary prevention of cardiovascular disease among patients with Low
197.
CenterWatch Clinical Research Center Profile (2069 …:
Ocular Steroid; Pediculocide; Quinolone Antibiotic; Red Blood Cell Production
Stimulant; Testosterone Gel; Topical Antibiotic; Topical Hormone Gel
198.
Study Posting (2623) — Trial #69732, Post Menopause, Aventura, FL:
The study will evaluate a combination medication of estrogen and testosterone
to alleviate these symptoms. To qualify:. Women 30 to 65 years old.
199.
Study Posting (713) — Trial #69076, Healthy Women Studies …:
should have a history of less than 6 menstrual cycles per year, as well as
elevated testosterone levels and/or problems with increased hair growth.
200.
Newly Approved Drug Therapies (733): dutasteride, GlaxoSmithKline:

These enzymes are responsible for converting testosterone into
dihydrotestosterone (DHT) in the prostate. In turn, high levels of DTH may
accumulate and

201.
Study Posting (1420) — Trial #49034, HIV, Los Angeles, CA:
The use of any steroids other than testosterone replacement therapy.
Participants with significant cardiac disease. Use of appetite stimulants within 6
202.
CenterWatch Clinical Research Center Profile (16): Hudson Valley …:
ED; prostate cancer; UTI; testosterone replacement; TUMT/urinary retention;
overactive bladder; high grade PIN; complex PSA; outpatient surgical pain

203.
CenterWatch Clinical Research Center Profile (16): Hudson Valley …:
ED; prostate cancer; UTI; testosterone replacement; TUMT/urinary retention;
overactive bladder; high grade PIN; complex PSA; outpatient surgical pain

204.
Study Posting (799) — Trial #66690, Erectile Dysfunction, Boston, MA:
A research study of an investigational drug that increases testosterone levels
in men. Study duration is 12 months and involves 4 outpatient vists with
205.
CenterWatch Clinical Research Center Profile (2380): LU Clinical …:
Males with BPH (Enlarged Prostate); Men Age 18 to 75 in New Jersey: Have you
been told you have Low Testosterone? Men age 18 to 75 in North Jersey: Have
206.
Study Posting (3039) — Trial #53015, Prostate Cancer, South …:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
207.
Study Posting (3039) — Trial #59283, Prostate Cancer, Milwaukee, WI:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
208.
Study Posting (3039) — Trial #59279, Prostate Cancer, Washington, DC:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
209.
Study Posting (3039) — Trial #53031, Prostate Cancer, Homewood, AL:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron

210.
Centerwatch:
Low Testosterone Research Study. Various Cities; Research Site Rosuvastatin
in the primary prevention of cardiovascular disease among patients with Low

211.
Study Posting (3039) — Trial #58284, Prostate Cancer, Anchorage, AK:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
212.
Study Posting (3039) — Trial #61872, Prostate Cancer, New …:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
213.
Study Posting (3039) — Trial #53025, Prostate Cancer, Santa …:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
214.
Study Posting (3039) — Trial #58280, Prostate Cancer, Waterbury, CT:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
215.
Study Posting (3039) — Trial #59284, Prostate Cancer, Albuquerque, NM:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron

216.
Study Posting (3039) — Trial #61872, Prostate Cancer, New …:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
217.
Study Posting (3039) — Trial #53025, Prostate Cancer, Santa …:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
218.
Study Posting (3039) — Trial #58280, Prostate Cancer, Waterbury, CT:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
219.
Study Posting (3039) — Trial #59284, Prostate Cancer, Albuquerque, NM:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
220.
Listing of Newly Approved Drug Therapies (1997):
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza; Approved
December 1997. Teveten; Treatment for hypertension; SmithKline Beecham;

221.
Study Posting (3039) — Trial #66472, Prostate Cancer, Weatherford, TX:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
222.
Study Posting (3039) — Trial #64255, Prostate Cancer, Washington, DC:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron

223.
Study Posting (3039) — Trial #53017, Prostate Cancer, Aventura, FL:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron

224.
Study Posting (3039) — Trial #53022, Prostate Cancer, Torrance, CA:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
225.
UrologyHealth.org – Clinical Trials Resource Center:
Testim – A research study for men with low testosterone. New York; University
Urology Associates A research study for men with erectile dysfunction
226.
Study Posting (3039) — Trial #53022, Prostate Cancer, Torrance, CA:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
227.
Study Posting (16) — Trial #40540, Prostate Cancer, Waterbury, CT:
We are evaluating an investigational medication to determine its testosterone
and pain-lowering capabilities. The study medication is administered twice
228.
Study Posting (3039) — Trial #56700, Prostate Cancer, Aurora, CO:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron
229.
Publications | Black AIDS Institute:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
230.
Centerwatch:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
231.
Study Posting (3039) — Trial #59285, Prostate Cancer, Long Beach, CA:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron

232.
Publications | Black AIDS Institute:
Exclusion Criteria:. Current or previous treatment for diabetes. The use of
any steroids other than testosterone replacement therapy.
233.
Study Posting (3039) — Trial #61873, Prostate Cancer, Richmond, VA:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron

234.
Study Posting (3039) — Trial #66471, Prostate Cancer, Fort Worth, TX:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron

235.
Study Posting (3039) — Trial #59281, Prostate Cancer, Garden City, NY:
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent
with orchiectomy or continuous treatment with GnRH agonists [such as Lupron

236.
Florida Prostate Cancer Network – ClinicalTrials Resource Center:
selective androgen receptor modulator ostarine, for the treatment of andropause,
sarcopenia, and other symptoms of testosterone deficiency.
237.
Thomson CenterWatch – Clinical Trials Resource Center:
selective androgen receptor modulator ostarine, for the treatment of andropause,
sarcopenia, and other symptoms of testosterone deficiency.
238.
BioWorld | Clinical Trials Resource Center:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
239.
Drugs Approved by the FDA (1997):
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza; Approved
December 1997. Teveten; Treatment for hypertension; SmithKline Beecham;
240.
The American Pain Foundation:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995

241.
UrologyHealth.org – Clinical Trials Resource Center:
These enzymes are responsible for converting testosterone into
dihydrotestosterone (DHT) in the prostate. In turn, high levels of DTH may
accumulate and
242.
AAFA Home Page:
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza; Approved
December 1997. Teveten; Treatment for hypertension; SmithKline Beecham;
243.
BioWorld | Clinical Trials Resource Center:
Boise; Radiant Research – Boise Low Testosterone Research Study. Various Cities;
Research Site Rosuvastatin in the primary prevention of cardiovascular
244.
Centerwatch:
Testim – A research study for men with low testosterone. New York; University
Urology Associates A research study for men with erectile dysfunction
245.
Centerwatch:
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza; Approved
December 1997. Teveten; Treatment for hypertension; SmithKline Beecham;

246.
Newly Approved Drug Therapies (23): Androderm (Testosterone …:
Listing for Androderm (Testosterone Transdermal System) in FDA Approved Drug
Therapies Archives from CenterWatch Clinical Trials Listing Service.
247.
Newly Approved Drug Therapies (611): AndroGel testosterone gel …:
Listing for AndroGel testosterone gel in FDA Approved Drug Therapies Archives
from CenterWatch Clinical Trials Listing Service.
Information for AndroGel, FDA approved drug therapies archives from CenterWatch
clinical trials.
248.
Disease Category Listing (646): Low Testosterone:
CenterWatch Listing of Clinical Research Trials for Low Testosterone.
249.
Study Posting (2380) — Trial #68632, Low Testosterone …:
CenterWatch Clinical Research Trial Posting for Men Age 18 to 75 in New Jersey:
Have you been told you have Low Testosterone?

250.
Study Posting (2380) — Trial #54769, Low Testosterone …:
CenterWatch Clinical Research Trial Posting for Men age 18 to 75 in North Jersey:
Have you been told you have Low Testosterone?

251.
Study Posting (2380) — Trial #54770, Low Testosterone …:
CenterWatch Clinical Research Trial Posting for To the Viagra user: Do you have
these problems? Lack of energy, Low sex drive, Falling asleep after dinner.
252.
Newly Approved Drug Therapies (810): Testim, Auxilium Pharmaceuticals:
Testim is an externally administered testosterone supplement, Testosterone is
responsible for normal growth and development of the male sex organs

253.
RESOLVE: The National Infertility Association:
Men Age 18 to 75 in New Jersey: Have you been told you have Low Testosterone?
Lawrenceville; LU Clinical Research Men age 18 to 75 in North Jersey: Have
254.
Drugs Approved by the FDA:
can be placed on different parts of the body, boosts testosterone levels.
a condition in which the body produces inadequate levels of testosterone.
255.
Drugs Approved by the FDA:
conditions associated with a deficiency or absence of endogenous testosterone
The gel is absorbed through the skin and delivers testosterone to the
256.
The SHADE Foundation – The Curt and Shonda Schilling Melanoma …:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
257.
Publications | Black AIDS Institute:
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza; Approved
December 1997. Teveten; Treatment for hypertension; SmithKline Beecham;
258.
BioWorld | Clinical Trials Resource Center:
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza; Approved
December 1997. Teveten; Treatment for hypertension; SmithKline Beecham;
259.
WebMD Health Gateway to CenterWatch:
Low Testosterone Research Study. Various Cities; Research Site Rosuvastatin
in the primary prevention of cardiovascular disease among patients with Low
260.
The American Pain Foundation:
Ocular Steroid; Pediculocide; Quinolone Antibiotic; Red Blood Cell Production
Stimulant; Testosterone Gel; Topical Antibiotic; Topical Hormone Gel

261.
The American Pain Foundation:
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza; Approved
December 1997. Teveten; Treatment for hypertension; SmithKline Beecham;
262.
Study Posting (713) — Trial #69069, Polycystic Ovarian Syndrome …:
should have a history of less than 6 menstrual cycles per year, as well as
elevated testosterone levels and/or problems with increased hair growth.
263.
RESOLVE: The National Infertility Association:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
264.
BioWorld | Clinical Trials Resource Center:
Sexual Dysfunction; Sexually Transmitted Diseases; Sinusitis; Sleep Apnea;
Social Anxiety Disorder; Stroke; Tennis Elbow; Testosterone Therapy
265.
Centerwatch:
Testosterone Replacement and Physical Function in HIV-Associated Weight Loss.
Los Angeles; UCLA Medical Center Phase II, double blind,
266.
Trial Information:
A research study of an investigational drug that increases testosterone levels
in men. Study duration is 12 months and involves 4 outpatient vists with
267.
Drugs Approved by the FDA:
which act by directly blocking the cancer-promoting activities of androgens,
or male sex hormones, of which the principal one is testosterone.
268.
RESOLVE: The National Infertility Association:
Ocular Steroid; Pediculocide; Quinolone Antibiotic; Red Blood Cell Production
Stimulant; Testosterone Gel; Topical Antibiotic; Topical Hormone Gel
269.
Drugs Approved by the FDA:

These enzymes are responsible for converting testosterone into
dihydrotestosterone (DHT) in the prostate. In turn, high levels of DTH may
accumulate and

270.
Centerwatch:
the ages of 20-50 for a 16 week research study of the effects of testosterone
and estrogen on bone metabolism, body composition, strength, and symptoms.
271.
Clinical Trials Resource Center:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
272.
Clinical Trials Resource Center – Hepatitis Foundation International:
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza; Approved
December 1997. Teveten; Treatment for hypertension; SmithKline Beecham;
273.
Clinical Trials Resource Center:
selective androgen receptor modulator ostarine, for the treatment of andropause,
sarcopenia, and other symptoms of testosterone deficiency.
274.
RESOLVE: The National Infertility Association:
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza; Approved
December 1997. Teveten; Treatment for hypertension; SmithKline Beecham;
275.
BioWorld | Clinical Trials Resource Center:
Ocular Steroid; Pediculocide; Quinolone Antibiotic; Red Blood Cell Production
Stimulant; Testosterone Gel; Topical Antibiotic; Topical Hormone Gel

276.
UrologyHealth.org – Clinical Trials Resource Center:
Ocular Steroid; Pediculocide; Quinolone Antibiotic; Red Blood Cell Production
Stimulant; Testosterone Gel; Topical Antibiotic; Topical Hormone Gel

277.
Centerwatch:
Philadelphia; University of Pennsylvania Health System Recruiting men with
pituitary disease who have testosterone and growth hormone deficiencies.
278.
Healthy Patient Studies:
Low Testosterone Research Study. Various Cities; Research Site Rosuvastatin
in the primary prevention of cardiovascular disease among patients with Low
279.
BioWorld | Clinical Trials Resource Center:
which act by directly blocking the cancer-promoting activities of androgens,
or male sex hormones, of which the principal one is testosterone.
280.
AADE | Clinical Trials Resource Center:
Males with BPH (Enlarged Prostate); Men Age 18 to 75 in New Jersey: Have you
been told you have Low Testosterone? Men age 18 to 75 in North Jersey: Have

281.
AADE | Clinical Trials Resource Center:
Ocular Steroid; Pediculocide; Quinolone Antibiotic; Red Blood Cell Production
Stimulant; Testosterone Gel; Topical Antibiotic; Topical Hormone Gel
282.
Centerwatch:
Ocular Steroid; Pediculocide; Quinolone Antibiotic; Red Blood Cell Production
Stimulant; Testosterone Gel; Topical Antibiotic; Topical Hormone Gel
283.
Clinical Trials Resource Center – Hepatitis Foundation International:
Ocular Steroid; Pediculocide; Quinolone Antibiotic; Red Blood Cell Production
Stimulant; Testosterone Gel; Topical Antibiotic; Topical Hormone Gel
284.
Centerwatch:
Sexual Dysfunction; Sexually Transmitted Diseases; Sinusitis; Sleep Apnea;
Social Anxiety Disorder; Stroke; Tennis Elbow; Testosterone Therapy
285.
Centerwatch:
A research study of an investigational drug that increases testosterone levels
in men. Study duration is 12 months and involves 4 outpatient vists with

286.
AADE | Clinical Trials Resource Center:
Ocular Steroid; Pediculocide; Quinolone Antibiotic; Red Blood Cell Production
Stimulant; Testosterone Gel; Topical Antibiotic; Topical Hormone Gel
287.
Centerwatch:
Ocular Steroid; Pediculocide; Quinolone Antibiotic; Red Blood Cell Production
Stimulant; Testosterone Gel; Topical Antibiotic; Topical Hormone Gel
288.
Clinical Trials Resource Center – Hepatitis Foundation International:
Ocular Steroid; Pediculocide; Quinolone Antibiotic; Red Blood Cell Production
Stimulant; Testosterone Gel; Topical Antibiotic; Topical Hormone Gel

289.
Centerwatch:
Sexual Dysfunction; Sexually Transmitted Diseases; Sinusitis; Sleep Apnea;
Social Anxiety Disorder; Stroke; Tennis Elbow; Testosterone Therapy
290.
Centerwatch:
A research study of an investigational drug that increases testosterone levels
in men. Study duration is 12 months and involves 4 outpatient vists with

291.
Centerwatch:
A research study of an investigational drug that increases testosterone levels
in men. Study duration is 12 months and involves 4 outpatient vists with
292.
AADE | Clinical Trials Resource Center:
Philadelphia; University of Pennsylvania Health System Recruiting men with
pituitary disease who have testosterone and growth hormone deficiencies.
293.
Trial Information:
the ages of 20-50 for a 16 week research study of the effects of testosterone
and estrogen on bone metabolism, body composition, strength, and symptoms.
294.
Epilepsy Fdn.-Research Home Page:
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza; Approved
December 1997. Teveten; Treatment for hypertension; SmithKline Beecham;

295.
First Clinical Research – Services:
selective androgen receptor modulator ostarine, for the treatment of andropause,
sarcopenia, and other symptoms of testosterone deficiency.
296.
WebMD Health Gateway to CenterWatch:
Testosterone Replacement and Physical Function in HIV-Associated Weight Loss.
Los Angeles; UCLA Medical Center Phase II, double blind,

297.
Centerwatch:
18 years and older are invited to participate in a research study on testosterone
and its effects on muscle strength and physical function.
298.
Centerwatch:
These enzymes are responsible for converting testosterone into
dihydrotestosterone (DHT) in the prostate. In turn, high levels of DTH may
accumulate and
299.
AADE | Clinical Trials Resource Center:
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza; Approved
December 1997. Teveten; Treatment for hypertension; SmithKline Beecham;
300.
PalmOne.com Clinical Trials Resource Center:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
301.
Centerwatch:
which act by directly blocking the cancer-promoting activities of androgens,
or male sex hormones, of which the principal one is testosterone.
302.
Centerwatch:
Males with BPH (Enlarged Prostate); Men Age 18 to 75 in New Jersey: Have you
been told you have Low Testosterone? Men age 18 to 75 in North Jersey: Have
303.
UrologyHealth.org – Clinical Trials Resource Center:
ED; prostate cancer; UTI; testosterone replacement; TUMT/urinary retention;
overactive bladder; high grade PIN; complex PSA; outpatient surgical pain
304.
UrologyHealth.org – Clinical Trials Resource Center:
Group of New Mexico has performed clinical studies on prostate and bladder
cancer, BPH, female incontinence, prostatitis and testosterone studies.
305.
AADE | Clinical Trials Resource Center:
Sexual Dysfunction; Sexually Transmitted Diseases; Sinusitis; Sleep Apnea;
Social Anxiety Disorder; Stroke; Tennis Elbow; Testosterone Therapy
306.
Centerwatch:
The combination of norethindrone acetate and ethinyl estradiol increases sex
hormone binding globulin (SHBG) and decreases free testosterone; however,

307.
Centerwatch:
within the past 12 months of finasteride (Proscar or Propecia),
dutasteride (Avodart), testosterone, or drugs that can block the action of male
hormones
308.
UrologyHealth.org – Clinical Trials Resource Center:
A research study of an investigational drug that increases testosterone levels
in men. Study duration is 12 months and involves 4 outpatient vists with
309.
Clinical Trials Resource Center:
selective androgen receptor modulator ostarine, for the treatment of andropause,
sarcopenia, and other symptoms of testosterone deficiency.
310.
Clinical Trials Resource Center:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
311.
Clinical Trials Resource Center:
which act by directly blocking the cancer-promoting activities of androgens,
or male sex hormones, of which the principal one is testosterone.
312.
Clinical Trials Resource Center:
Sexual Dysfunction; Sexually Transmitted Diseases; Sinusitis; Sleep Apnea;
Social Anxiety Disorder; Stroke; Tennis Elbow; Testosterone Therapy
313.
AADE | Clinical Trials Resource Center:
These enzymes are responsible for converting testosterone into
dihydrotestosterone (DHT) in the prostate. In turn, high levels of DTH may
accumulate and
314.
Clinical Trials Resource Center:
These enzymes are responsible for converting testosterone into
dihydrotestosterone (DHT) in the prostate. In turn, high levels of DTH may
accumulate and
315.
Clinical Trials Resource Center:
The combination of norethindrone acetate and ethinyl estradiol increases sex
hormone binding globulin (SHBG) and decreases free testosterone; however,

316.
Listing of Newly Approved Drug Therapies (1997):
Testoderm TTS CIII; Treatment for testosterone deficiency; Alza; Approved
December 1997. Teveten; Treatment for hypertension; SmithKline Beecham;

317.
CenterWatch Clinical Research Center Profile (430): Radiant …:
High Blood Pressure Research Study; Low Testosterone Research Study; New Psoriasis
Study Being Conducted. Novartis is conducting a 10-12 week clinical

318.
CenterWatch Clinical Research Center Profile (488): University of …:
Recruiting men with pituitary disease who have testosterone and growth hormone
deficiencies. Smokers and Non-smokers; Smokers Wanted.
319.
CenterWatch Clinical Research Center Profile (3115): University …:
Prostatitis–Study for men with chronic non-bacterial prostatitis. Testim -
A research study for men with low testosterone.
320.
CenterWatch Clinical Research Center Profile (430): Radiant …:
Could you have metabolic syndrome? Does your teenager suffer from Migraine
Headache Attacks? GERD Research Study; Low Testosterone Research Study
321.
RESOLVE: The National Infertility Association:
Uterine Disorders; Uterine Fibroids; Vaginal Infection; Vaginitis; Yeast Infections.
For men:. Impotence; Low Testosterone; Premature Ejaculation
322.
Cardiology/Vascular Diseases Drugs Approved by the FDA:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
323.
Centerwatch:
Liver Cancer (6); Liver Disease (5); Liver Disorders (5); Low Blood
Sodium (Hyponatremia); Low Testosterone (3); Mastectomy; Medical Prosthetics
324.
UrologyHealth.org – Clinical Trials Resource Center:
Genitourinary Prolapse; Gout (Hyperuricemia); Human Papilloma Virus (HPV);
Impotence; Interstitial Cystitis; Low Testosterone; Medical Prosthetics
325.
RESOLVE: The National Infertility Association:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995

326.
UrologyHealth.org – Clinical Trials Resource Center:
Genitourinary Prolapse; Gout (Hyperuricemia); Human Papilloma Virus (HPV);
Impotence; Interstitial Cystitis; Low Testosterone; Medical Prosthetics
327.
RESOLVE: The National Infertility Association:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
328.
Approved Drugs for Cardiology/Vascular Diseases:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
329.
AAFA Home Page:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
330.
RESOLVE: The National Infertility Association:
High Blood Pressure Research Study; Low Testosterone Research Study; New Psoriasis
Study Being Conducted. Novartis is conducting a 10-12 week clinical
331.
BioWorld | Clinical Trials Resource Center:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
332.
RESOLVE: The National Infertility Association:
Recruiting men with pituitary disease who have testosterone and growth hormone
deficiencies. Smokers and Non-smokers; Smokers Wanted.
333.
WebMD Health Gateway to CenterWatch:
Liver Cancer (6); Liver Disease (5); Liver Disorders (5); Low Blood
Sodium (Hyponatremia); Low Testosterone (3); Mastectomy; Medical Prosthetics
334.
Publications | Black AIDS Institute:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
335.
BioWorld | Clinical Trials Resource Center:
Liver Cancer (6); Liver Disease (6); Liver Disorders (6); Low Blood
Sodium (Hyponatremia); Low Testosterone (3); Mastectomy; Medical Prosthetics
336.
lipidhealth :: Helpful Resources:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
337.
Clinical Trials in Nephrology/Urology:
Liver Cancer (6); Liver Disease (5); Liver Disorders (5); Low Blood
Sodium (Hyponatremia); Low Testosterone (3); Mastectomy; Medical Prosthetics
338.
The American Pain Foundation:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
339.
UrologyHealth.org – Clinical Trials Resource Center:
High Blood Pressure Research Study; Low Testosterone Research Study; New Psoriasis
Study Being Conducted. Novartis is conducting a 10-12 week clinical
340.
The American Pain Foundation:
Recruiting men with pituitary disease who have testosterone and growth hormone
deficiencies. Smokers and Non-smokers; Smokers Wanted.

341.
The SHADE Foundation – The Curt and Shonda Schilling Melanoma …:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
342.
Clinical Trials Resource Center – Hepatitis Foundation International:

Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995

343.
Clinical Trials Resource Center:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
344.
AADE | Clinical Trials Resource Center:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
345.
AADE | Clinical Trials Resource Center:
GERD Research Study; Low Testosterone Research Study; Novartis is conducting
a 12 week clinical research study in patients that are 35 years old and
346.
Clinical Research Experience:
GERD Research Study; Low Testosterone Research Study; Novartis is conducting
a 12 week clinical research study in patients that are 35 years old and
347.
BioWorld | Clinical Trials Resource Center:
Could you have metabolic syndrome? Does your teenager suffer from Migraine
Headache Attacks? GERD Research Study; Low Testosterone Research Study
348.
BioWorld | Clinical Trials Resource Center:
GERD Research Study; High Blood Pressure Research Study; Low Testosterone
Research Study; New Psoriasis Study Being Conducted.
349.
BioWorld | Clinical Trials Resource Center:
Recruiting men with pituitary disease who have testosterone and growth hormone
deficiencies. Smokers and Non-smokers; Smokers Wanted.
350.
Centerwatch:
Recruiting men with pituitary disease who have testosterone and growth hormone
deficiencies. Smokers and Non-smokers; Smokers Wanted.
351.
Centerwatch:
GERD Research Study; High Blood Pressure Research Study; Low Testosterone
Research Study; New Psoriasis Study Being Conducted.
352.
Centerwatch:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
353.
Centerwatch:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
354.
UrologyHealth.org – Clinical Trials Resource Center:
Prostatitis–Study for men with chronic non-bacterial prostatitis. Testim -
A research study for men with low testosterone.

355.
AADE | Clinical Trials Resource Center:
GERD Research Study; High Blood Pressure Research Study; Low Testosterone
Research Study; New Psoriasis Study Being Conducted.

356.
Epilepsy Fdn.-Research Home Page:
GERD Research Study; Low Testosterone Research Study; Novartis is conducting
a 12 week clinical research study in patients that are 35 years old and

357.
Clinical Trials Resource Center – Hepatitis Foundation International:
GERD Research Study; High Blood Pressure Research Study; Low Testosterone
Research Study; New Psoriasis Study Being Conducted.
358.
UrologyHealth.org – Clinical Trials Resource Center:
Could you have metabolic syndrome? Does your teenager suffer from Migraine
Headache Attacks? GERD Research Study; Low Testosterone Research Study
359.
Epilepsy Fdn.-Research Home Page:
GERD Research Study; High Blood Pressure Research Study; Low Testosterone
Research Study; New Psoriasis Study Being Conducted.
360.
Clinical Trials Resource Center:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
361.
Clinical Trials Resource Center:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
362.
Clinical Trials Resource Center:
Androderm (Testosterone Transdermal System); Treatment for primary and secondary
hypogonadism; TheraTech; Approved on September 29, 1995
363.
Clinical Trials Resource Center:
Recruiting men with pituitary disease who have testosterone and growth hormone
deficiencies. Smokers and Non-smokers; Smokers Wanted.
364.
Clinical Trials Resource Center:
Recruiting men with pituitary disease who have testosterone and growth hormone
deficiencies. Smokers and Non-smokers; Smokers Wanted.
365.
Disease Category Listing (603): Diabetes – Type II:
Low Testosterone Research Study. Portland; Radiant Research – Portland Type
2 Diabetes Research Study. Portland; Radiant Research – Portland
366.
Centerwatch:
Low Testosterone Research Study. Portland; Radiant Research – Portland Type
2 Diabetes Research Study. Portland; Radiant Research – Portland
367.
AADE | Clinical Trials Resource Center:
Low Testosterone Research Study. Portland; Radiant Research – Portland Research
Study for Type II Diabetes. Portland; Radiant Research – Portland

368.
Epilepsy Fdn.-Research Home Page:
Company: Auxilium Pharmaceuticals Approval Status: Approved October 2002
Treatment for: Low Testosterone. General Information. Testim
369.
An online Healthcare and Medical Information Portal – Directory …:
Following a single intramuscular (IM) injection of Trelstar Depot to healthy male
volunteers, serum testosterone levels first increased, peaking on day 4, and
370.
The American Pain Foundation:
Plenaxis (abarelix for injectable suspension), a gonadotropin-releasing hormone
(GnRH) antagonist, lowers the male hormone testosterone in the blood stream.
371.
CenterWatch – StemCellHelp.org Clinical Trials Resource Center:
The purpose of this study is to find the best dose of FE200486 for reducing testosterone
levels in men with prostate cancer, to study the safety of this drug
372.
The SHADE Foundation – The Curt and Shonda Schilling Melanoma …:
Company: Alza Approval Status: Approved December 1997 Treatment for: testosterone
deficiency. General Information. Testoderm TTS CIII
373.
National Stroke:
Company: Alza Approval Status: Approved December 1997 Treatment for: testosterone
deficiency. General Information. Testoderm TTS CIII
374.
An online Healthcare and Medical Information Portal – Directory …:
Company: Alza Approval Status: Approved December 1997 Treatment for: testosterone
deficiency. General Information. Testoderm TTS CIII
375.
Resources – The Breast Cancer Fund:
Company: Alza Approval Status: Approved December 1997 Treatment for: testosterone
deficiency. General Information. Testoderm TTS CIII
376.
Resources – The Breast Cancer Fund:
cancer. General Information. Viadur is a testosterone suppression therapy
for the palliative treatment of advanced prostate cancer.
377.
CenterWatch – StemCellHelp.org Clinical Trials Resource Center: …
Trial Information. Summary: Recruiting men with pituitary disease who have
testosterone and growth hormone deficiencies. Both testosterone
378.
The SHADE Foundation – The Curt and Shonda Schilling Melanoma …:
Company: Auxilium Pharmaceuticals Approval Status: Approved October 2002
Treatment for: Low Testosterone. General Information. Testim
379.
An online Healthcare and Medical Information Portal – Directory …:
Drug Name: AndroGel testosterone gel. The gel is absorbed through the skin and
delivers testosterone to the patient for approximately 24 hours.
380.
MPIP – Clinical Trials Resource Center:
The purpose of this study is to find the best dose of FE200486 for reducing testosterone
levels in men with prostate cancer, to study the safety of this drug
381.
First Clinical Research – Services:
Following a single intramuscular (IM) injection of Trelstar Depot to healthy male
volunteers, serum testosterone levels first increased, peaking on day 4, and
382.
The SHADE Foundation – The Curt and Shonda Schilling Melanoma …:
Drug Name: Androderm (Testosterone Transdermal System). Androderm, a skin patch that
can be placed on different parts of the body, boosts testosterone levels.
383.
MPIP – Clinical Trials Resource Center:
Company: Auxilium Pharmaceuticals Approval Status: Approved October 2002
Treatment for: Low Testosterone. General Information. Testim
384.
National Stroke:
Company: Auxilium Pharmaceuticals Approval Status: Approved October 2002
Treatment for: Low Testosterone. General Information. Testim
385.
An online Healthcare and Medical Information Portal – Directory …:
Company: Auxilium Pharmaceuticals Approval Status: Approved October 2002
Treatment for: Low Testosterone. General Information. Testim
386.
Drugs Approved by the FDA (2000):
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000.
387.
Resources – The Breast Cancer Fund:
It works by blocking an enzyme called 5-alpha reductase, which is responsible
for the formation of dihydro-testosterone in a man’s body.

388.
Epilepsy Fdn.-Research Home Page:
Following a single intramuscular (IM) injection of Trelstar Depot to healthy male
volunteers, serum testosterone levels first increased, peaking on day 4, and
389.
First Clinical Research – Services:
The growth of prostate cancer can be stimulated by the male hormone testosterone.
Treatment with Zoladex as a subcutaneous injection
390.
An online Healthcare and Medical Information Portal – Directory …:
It works by blocking an enzyme called 5-alpha reductase, which is responsible
for the formation of dihydro-testosterone in a man’s body.

391.
Epilepsy Fdn.-Research Home Page:
Drug Name: AndroGel testosterone gel. The gel is absorbed through the skin and
delivers testosterone to the patient for approximately 24 hours.
392.
The SHADE Foundation – The Curt and Shonda Schilling Melanoma …:
Lupron Depot (three month, 22.5 mg) works by shutting down the production of the
hormone testosterone, which plays a significant role in the growth of prostate
393.
UroToday – UroToday Resources – Uro Resources
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000.
394.
MPIP – Clinical Trials Resource Center:
flashes. Serum testosterone levels may increase approximately 50 percent
above baseline during the first week of treatment. Like

 

395.
First Clinical Research – Services:
Lupron Depot (three month, 22.5 mg) works by shutting down the production of the
hormone testosterone, which plays a significant role in the growth of prostate
396.
MPIP – Clinical Trials Resource Center:
It works by blocking an enzyme called 5-alpha reductase, which is responsible
for the formation of dihydro-testosterone in a man’s body.
397.
An online Healthcare and Medical Information Portal – Directory …:
cancer. General Information. Viadur is a testosterone suppression therapy
for the palliative treatment of advanced prostate cancer.

398.
WebMD Health Gateway to CenterWatch:
Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
399.
National Stroke:
The combination of norethindrone acetate and ethinyl estradiol increases sex hormone
binding globulin (SHBG) and decreases free testosterone; however, the
400.
An online Healthcare and Medical Information Portal – Directory …:
cancer. General Information. Viadur is a testosterone suppression therapy
for the palliative treatment of advanced prostate cancer.
401.
Trial Information
These include estrogen, progestin or progesterone, testosterone (including transdermal
forms, ie, patches, topical creams, etc., some of which are OTC), DHEA
402.
Trial Information:
Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.

403.
An online Healthcare and Medical Information Portal – Directory …:
Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
404.
UroToday – UroToday Resources – Uro Resources:
Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
405.
UroToday – UroToday Resources – Uro Resources:
Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
406.
UroToday – UroToday Resources – Uro Resources:
Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
407.
Resources – The Breast Cancer Fund:
Following a single intramuscular (IM) injection of Trelstar Depot to healthy male
volunteers, serum testosterone levels first increased, peaking on day 4, and
408.
UroToday – UroToday Resources – Uro Resources:
Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
409.
UroToday – UroToday Resources – Uro Resources:
Clinical Trials: Low Testosterone. Lawrenceville; LU Clinical Research Men age 18
to 75 in North Jersey: Have you been told you have Low Testosterone?
410.
UroToday – UroToday Resources – Uro Resources:
Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
411.
UroToday – UroToday Resources – Uro Resources
Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
412.
IMF: Research: Clinical Trials Resource Center:
AndroGel testosterone gel; For testosterone replacement therapy in males with
testosterone deficiency; Unimed Pharmaceuticals; Approved February 2000.

413.
WebMD Health Gateway to CenterWatch:
Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
414.
The SHADE Foundation – The Curt and Shonda Schilling Melanoma …:
Summary: A Study of Testosterone Treatment for Men with Multiple Sclerosis. This
will be a 2-year study to test if testosterone may be beneficial in MS.
415.
Trial Information:
Serum testosterone levels <50 ng/dL documented in non-surgically castrated
patients within 21 days prior to randomization. Prior
416.
Trial Information:
Serum testosterone levels <50 ng/dL documented in non-surgically castrated
patients within 21 days prior to randomization. Prior
417.
WebMD Health Gateway to CenterWatch:
Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
418.
Drugs Approved by the FDA (1997):
Approved March 1997. Testoderm TTS CIII; Treatment for testosterone deficiency;
Alza; Approved December 1997. Teveten; Treatment for
419.
Trial Information:
Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
420.
The SHADE Foundation – The Curt and Shonda Schilling Melanoma …:
Trial Information. Summary: Recruiting men with pituitary disease who have
testosterone and growth hormone deficiencies. Both testosterone
421.
An online Healthcare and Medical Information Portal – Directory …:
 complementary medical information portal – directory locator of health related
websites, featuring the largest health care specific search directory on the Internet
422.
UroToday – UroToday Resources – Uro Resources
Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
423.
Trial Information
Serum testosterone levels <50 ng/dL documented in non-surgically castrated
patients within 21 days prior to randomization. Prior
424.
Trial Information:
Serum testosterone levels <50 ng/dL documented in non-surgically castrated
patients within 21 days prior to randomization. Prior
425.
An online Healthcare and Medical Information Portal – Directory …:
Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
426.
WebMD Health Gateway to CenterWatch: …
 Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent with
orchiectomy or continuous treatment with GnRH agonists [such as Lupron
427.
An online Healthcare and Medical Information Portal – Directory …:
Principal Investigator(s): Evan R. Goldfischer, MD. Indication areas: ED; prostate
cancer; UTI; testosterone replacement; TUMT/urinary retention; overactive bladder
428.
UroToday – UroToday Resources – Uro Resources:
 Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
429.
An online Healthcare and Medical Information Portal – Directory …:
Principal Investigator(s): Evan R. Goldfischer, MD. Indication areas: ED; prostate
cancer; UTI; testosterone replacement; TUMT/urinary retention; overactive bladder
430.
UroToday – UroToday Resources – Uro Resources: .
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent with
orchiectomy or continuous treatment with GnRH agonists [such as Lupron
431.
UroToday – UroToday Resources – Uro Resources: …
 Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
432.
WebMD Health Gateway to CenterWatch:
 Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
433.
UroToday – UroToday Resources – Uro Resources:
Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
434.
UroToday – UroToday Resources – Uro Resources:
Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
(Avodart), testosterone, or drugs that can block the action of male hormones.
435.
Trial Information: …
Castrate testosterone levels < 50 ng/dL (reported as 0.50 ng/mL) consistent with
orchiectomy or continuous treatment with GnRH agonists [such as Lupron
436.
Trial Information: …
Serum testosterone levels <50 ng/dL documented in non-surgically castrated
patients within 21 days prior to randomization. Prior
437.
UroToday – UroToday Resources – Uro Resources:
Clinical Trials: Low Testosterone. Lawrenceville; LU Clinical Research Men age 18
to 75 in North Jersey: Have you been told you have Low Testosterone?